Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 23 October 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Oral direct-acting antivirals is cost-effective in patients waitlisted for liver transplant in the USA

A study in July's issue of Hepatology examines the treatment of patients waitlisted for liver transplant with all-oral direct-acting antivirals is a cost-effective treatment strategy in the United States.

News image

All-oral direct acting antivirals have been shown to have high safety and efficacy in treating patients with hepatitis C virus (HCV) awaiting liver transplant. 

However, there is limited empirical evidence comparing the health and economic outcomes associated with treating patients pre-liver transplant versus post-liver transplant. 

Dr Zobair Younossi and colleagues analyzed the cost-effectiveness of pre-liver transplant versus post-liver transplant treatment with an all-oral direct acting antivirals regimen among HCV patients with hepatocellular carcinoma or decompensated cirrhosis. 

The researchers constructed decision-analytic Markov models of the natural disease progression of HCV in hepatocellular carcinoma patients and decompensated cirrhosis patients waitlisted for liver transplant. 

The model followed hypothetical cohorts of 1,000 patients with a mean age of 50 over a 30-year time horizon from a third-party US payer perspective and estimated their health and cost outcomes based on pre-liver transplant versus post-liver transplant treatment with an all-oral direct acting antivirals regimen. 

The pre-liver transplant treatment strategy resulted in 12 per-patient quality-adjusted life years
Hepatology
Transition probabilities and utilities were based on the literature and hepatologist consensus. 

The team sourced sustained virological response rates from ASTRAL-4, SOLAR-1, and SOLAR-2. 

Costs were sourced from RedBook, Medicare fee schedules, and published literature. 

In the hepatocellular carcinoma analysis, the pre-liver transplant treatment strategy resulted in 12 per-patient quality-adjusted life years and $365,948 per patient lifetime costs versus 10 and $283,696, respectively, in the post-liver transplant arm. 

In the decompensated cirrhosis analysis, the pre-liver transplant treatment strategy resulted in 9 per-patient quality-adjusted life years and $304,800 per patient lifetime costs versus 8.7 and $283,789, respectively, in the post-liver transplant arm. 

The researchers found that the pre-liver transplant treatment strategy was the most cost-effective in both populations with an incremental cost-effectiveness ratio of $74,255 in hepatocellular carcinoma, and $36,583 in decompensated cirrhosis. 

Sensitivity and scenario analyses showed that results were most sensitive to the utility of patients post-liver transplant, treatment sustained virological response rates, liver transplant costs, and baseline Model for End-Stage Liver Disease score.

Dr Younossi's team comments, "The timing of initiation of antiviral treatment for HCV patients with hepatocellular carcinoma or decompensated cirrhosis relative to liver transplant is an important area of clinical and policy research."

"Our results indicate that pre-liver transplant treatment with a highly effective, all-oral direct acting antivirals regimen provides the best health outcomes and is the most cost-effective strategy for the treatment of HCV patients with hepatocellular carcinoma or decompensated cirrhosis waitlisted for liver transplant."

Hepatology 2017: 66(1): 46–56
06 July 2017

Go to top of page Email this page Email this page to a colleague

 23 October 2017 
NAFLD-related hepatocellular carcinoma in liver resection
 23 October 2017 
Outcome of hepatic sarcoidosis
 23 October 2017 
Irradiated rectal cancer and chemoradiotherapy
 20 October 2017 
Hospital readmissions reduction program
 20 October 2017 
Conversion of planned colonoscopy to sigmoidoscopy
 20 October 2017 
Food elimination diets for treatment of adults with eosinophilic esophagitis
 19 October 2017 
Fecal immunochemical tests in colorectal cancer screening
 19 October 2017 
Surgical anastomosis at 1-year colorectal cancer surveillance
 19 October 2017 
Current management of chylous ascites
 18 October 2017 
Hep E seroprevalence and hemodialysis
 18 October 2017 
Prebiotic and changes in the human gut microbiota
 18 October 2017 
Predicting recurrence after curative rectal cancer surgery
 17 October 2017 
Laparoscopic surgery use in Medicare patients with colon cancer
 17 October 2017 
Medication nonadherence and health care costs
 17 October 2017 
Asthma and IBD development
 16 October 2017 
Colorectal cancer screening and postpolypectomy surveillance colonoscopy
 16 October 2017 
Continuity of care after colorectal surgery
 16 October 2017 
Breastfeeding and the risk of IBD
 13 October 2017 
Treating patients with HCV and severe renal impairment
 13 October 2017 
Blood pressure management during abdominal surgery
 13 October 2017 
Food elimination diets for eosinophilic esophagitis
 12 October 2017 
Global recurrence of H. pylori
 12 October 2017 
Colonoscopy in an organized colorectal cancer screening program 
 12 October 2017 
Predicting advanced fibrosis in chronic hepatitis B
 11 October 2017 
Fecal microbiota transplantation for ulcerative colitis
 11 October 2017 
Sexual functioning in Hep C
 11 October 2017 
Ulcerative proctitis in pediatric-onset UC
 10 October 2017 
Quality standards in upper gastrointestinal endoscopy
 10 October 2017 
Eosinophilic esophagitis and swallowed topical corticosteroids
 10 October 2017 
Follow-up of positive results on fecal blood tests
 09 October 2017 
Diverticulitis and emergency department burden
 09 October 2017 
Global recurrence rate of H. pylori
 09 October 2017 
Clostridium difficile infection after ileostomy reversal
 06 October 2017 
Predicting nontreatment for Hep C
 06 October 2017 
Cow's milk–based formula and development of celiac disease
 06 October 2017 
Propofol for outpatient colonoscopy
 05 October 2017 
Pediatric candidates on the transplant wait list
 05 October 2017 
Incidence of sepsis in the USA
 05 October 2017 
Quality of life after chemoradiation in rectal cancer
 04 October 2017 
Peptic ulcer disease diagnosed in acute upper endoscopy
 04 October 2017 
Clinical practice guidelines in colon cancer
 04 October 2017 
Rural residence and risk of IBD
 03 October 2017 
Novel candidate risk genes for IBD
 03 October 2017 
Antibody tests and detecting celiac disease
 03 October 2017 
Environmental factors and IBD
 02 October 2017 
Full publication of Gastroenerology abstracts
 02 October 2017 
Interferon-free therapy in advanced liver disease
 02 October 2017 
Burden of NAFLD with advanced fibrosis in the USA
 29 September 2017 
Inpatient Gastroenterology training experience
 29 September 2017 
Proteomic analysis of IBD
 28 September 2017 
Social networking-based discussion group by ERCP doctors
 28 September 2017 
Incidence of biopsy-verified celiac disease
 27 September 2017 
Predictors of nonadherence in IBD
 27 September 2017 
Hep C treatment in the era of direct-acting anti-viral agents
 27 September 2017 
Function of trypsin-3 in IBS
 26 September 2017 
Chronic pancreatitis and pancreatic cancer risk
 26 September 2017 
Factors associated with the risk of metachronous gastric neoplasm
 26 September 2017 
Treatment of hyperactive delirium in advanced cancer
 25 September 2017 
Lenalidomide for advanced liver cancer
 25 September 2017 
Silibinin nanoparticles inhibit HCV infection

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us